Cue Biopharma Capital Expenditures (CapEx) Growth & History (CUE)
Cue Biopharma's capital expenditures (capex) was $177,000 for fiscal 2025.
View full Cue Biopharma company overviewCue Biopharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $177,000 | $111,000 | +168.18% |
| 2024 | 2024-12-31 | $66,000 | $66,000 | — |
| 2023 | 2023-12-31 | $0 | −$171,000 | — |
| 2022 | 2022-12-31 | $171,000 | −$742,039 | −81.27% |
| 2021 | 2021-12-31 | $913,039 | $317,780 | +53.39% |
| 2020 | 2020-12-31 | $595,259 | $548,906 | +1184.19% |
| 2019 | 2019-12-31 | $46,353 | −$1.8M | −97.50% |
| 2018 | 2018-12-31 | $1.9M | $824,304 | +80.03% |
| 2017 | 2017-12-31 | $1.0M | — | — |
Cue Biopharma quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$27,000 | — |
| Q1 2026 | 2026-03-31 | $121,000 | −$29,000 | −19.33% |
| Q4 2025 | 2025-12-31 | $0 | −$2,000 | — |
| Q3 2025 | 2025-09-30 | $0 | −$1,000 | — |
| Q2 2025 | 2025-06-30 | $27,000 | $17,000 | +170.00% |
| Q1 2025 | 2025-03-31 | $150,000 | $95,000 | +172.73% |
| Q4 2024 | 2024-12-31 | $2,000 | $2,000 | — |
| Q3 2024 | 2024-09-30 | $1,000 | $1,000 | — |
| Q2 2024 | 2024-06-30 | $10,000 | $10,000 | — |
| Q1 2024 | 2024-03-31 | $55,000 | $55,000 | — |
| Q4 2023 | 2023-12-31 | $0 | −$1,000 | — |
| Q3 2023 | 2023-09-30 | $0 | −$78,000 | — |
| Q2 2023 | 2023-06-30 | $0 | −$65,000 | — |
| Q1 2023 | 2023-03-31 | $0 | −$27,000 | — |
| Q4 2022 | 2022-12-31 | $1,000 | $961 | +2464.10% |
| Q3 2022 | 2022-09-30 | $78,000 | $65,000 | +500.00% |
| Q2 2022 | 2022-06-30 | $65,000 | −$187,000 | −74.21% |
| Q1 2022 | 2022-03-31 | $27,000 | −$621,000 | −95.83% |
| Q4 2021 | 2021-12-31 | $39 | — | — |
| Q3 2021 | 2021-09-30 | $13,000 | −$333,000 | −96.24% |
| Q2 2021 | 2021-06-30 | $252,000 | — | — |
| Q1 2021 | 2021-03-31 | $648,000 | — | — |
| Q3 2020 | 2020-09-30 | $346,000 | $329,000 | +1935.29% |
| Q4 2019 | 2019-12-31 | $10,353 | −$109,893 | −91.39% |
| Q3 2019 | 2019-09-30 | $17,000 | −$284,000 | −94.35% |
| Q2 2019 | 2019-06-30 | $0 | −$760,000 | — |
| Q1 2019 | 2019-03-31 | $19,000 | −$654,000 | −97.18% |
| Q4 2018 | 2018-12-31 | $120,246 | $101,304 | +534.81% |
| Q3 2018 | 2018-09-30 | $301,000 | $93,000 | +44.71% |
| Q2 2018 | 2018-06-30 | $760,000 | $513,000 | +207.69% |
| Q1 2018 | 2018-03-31 | $673,000 | $117,000 | +21.04% |
| Q4 2017 | 2017-12-31 | $18,942 | — | — |
| Q3 2017 | 2017-09-30 | $208,000 | — | — |
| Q2 2017 | 2017-06-30 | $247,000 | — | — |
| Q1 2017 | 2017-03-31 | $556,000 | — | — |
Cue Biopharma capital expenditures (capex) trends
Over the last five fiscal years, Cue Biopharma's capital expenditures (capex) decreased from $595,259 to $177,000, a change of −$418,259. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cue Biopharma source filings ↗